Aruna Bio
- Biotech or pharma, therapeutic R&D
Aruna Bio is a clinical-stage biotech company pioneering neural stem cell-derived exosomes to treat stroke and other CNS diseases. Leveraging decades of expertise in human neural stem cell biology, Aruna was the first to commercialize neural stem cells from human pluripotent stem cells. This led to a key insight: the cells' therapeutic power resided in the exosomes they secreted.
Exosomes are nanoscale vesicles that naturally modulate inflammation, promote recovery, and restore balance after CNS injury. AB126, Aruna’s lead candidate, is a native exosome product from a proprietary neural stem cell line. It crosses the blood-brain barrier, targets inflamed tissue, and acts on multiple disease pathways simultaneously.
In 2023, AB126 became the first neural exosome therapy to receive FDA IND clearance for a CNS indication. Aruna Bio is raising $15M to initiate a first-in-human clinical trial in stroke, a major inflection point for exosome-based therapeutics.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}